405 related articles for article (PubMed ID: 31722230)
1. Proteomic research in sarcomas - current status and future opportunities.
Burns J; Wilding CP; L Jones R; H Huang P
Semin Cancer Biol; 2020 Apr; 61():56-70. PubMed ID: 31722230
[TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomic studies addressing unmet clinical needs in sarcoma.
Connolly EA; Grimison PS; Horvath LG; Robinson PJ; Reddel RR
Front Oncol; 2023; 13():1126736. PubMed ID: 37197427
[TBL] [Abstract][Full Text] [Related]
3. Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
Milighetti M; Krasny L; Lee ATJ; Morani G; Szecsei C; Chen Y; Guljar N; McCarthy F; Wilding CP; Arthur A; Fisher C; Judson I; Thway K; Cheang MCU; Jones RL; Huang PH
J Proteomics; 2021 Jun; 241():104236. PubMed ID: 33895336
[TBL] [Abstract][Full Text] [Related]
4. Current status of proteomics of soft tissue sarcomas.
Kondo T
Expert Rev Proteomics; 2017 Dec; 14(12):1131-1140. PubMed ID: 29039718
[TBL] [Abstract][Full Text] [Related]
5. Novel Aspects of Genetics, Molecular Biology and Clinical Oncology of Sarcomas.
Houfková K; Hatina J
Klin Onkol; 2020; 33(1):66-78. PubMed ID: 32075391
[TBL] [Abstract][Full Text] [Related]
6. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas.
Suehara Y; Kondo T; Fujii K; Hasegawa T; Kawai A; Seki K; Beppu Y; Nishimura T; Kurosawa H; Hirohashi S
Proteomics; 2006 Aug; 6(15):4402-9. PubMed ID: 16807943
[TBL] [Abstract][Full Text] [Related]
7. Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types.
Murray E; Hernychová L; Scigelova M; Ho J; Nekulova M; O'Neill JR; Nenutil R; Vesely K; Dundas SR; Dhaliwal C; Henderson H; Hayward RL; Salter DM; Vojtěšek B; Hupp TR
J Proteome Res; 2014 May; 13(5):2543-59. PubMed ID: 24661138
[TBL] [Abstract][Full Text] [Related]
8. The proteomic landscape of soft tissue sarcomas.
Burns J; Wilding CP; Krasny L; Zhu X; Chadha M; Tam YB; Ps H; Mahalingam AH; Lee ATJ; Arthur A; Guljar N; Perkins E; Pankova V; Jenks A; Djabatey V; Szecsei C; McCarthy F; Ragulan C; Milighetti M; Roumeliotis TI; Crosier S; Finetti M; Choudhary JS; Judson I; Fisher C; Schuster EF; Sadanandam A; Chen TW; Williamson D; Thway K; Jones RL; Cheang MCU; Huang PH
Nat Commun; 2023 Jun; 14(1):3834. PubMed ID: 37386008
[TBL] [Abstract][Full Text] [Related]
9. Novel treatment targets in sarcoma: more than just the GIST.
Shoushtari AN; Van Tine BA; Schwartz GK
Am Soc Clin Oncol Educ Book; 2014; ():e488-95. PubMed ID: 24857144
[TBL] [Abstract][Full Text] [Related]
10. [Targeted therapy of sarcomas].
Cassier PA; Dufresne A; El Sayadi H; Pissaloux D; Alberti L; Decouvelaere AV; Ranchere D; Ray-Coquard I; Blay JY
Bull Cancer; 2008 Oct; 95(10):963-74. PubMed ID: 19004727
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of soft tissue sarcoma.
Suehara Y
Int J Clin Oncol; 2011 Apr; 16(2):92-100. PubMed ID: 21384281
[TBL] [Abstract][Full Text] [Related]
12. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs in Different Histologies of Soft Tissue Sarcoma: A Comprehensive Review.
Smolle MA; Leithner A; Posch F; Szkandera J; Liegl-Atzwanger B; Pichler M
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28895916
[TBL] [Abstract][Full Text] [Related]
14. Mining sarcomas by proteomics approaches: Ewing sarcoma on the spotlight.
Mackintosh C; Madoz-Gúrpide J
Recent Pat Biotechnol; 2013 Aug; 7(2):98-111. PubMed ID: 23848272
[TBL] [Abstract][Full Text] [Related]
15. Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas.
Chadha M; Huang PH
Curr Treat Options Oncol; 2022 Jan; 23(1):78-88. PubMed ID: 35171456
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas.
Merry E; Thway K; Jones RL; Huang PH
NPJ Precis Oncol; 2021 Mar; 5(1):17. PubMed ID: 33674685
[TBL] [Abstract][Full Text] [Related]
17. Options for treating different soft tissue sarcoma subtypes.
Ray-Coquard I; Serre D; Reichardt P; Martín-Broto J; Bauer S
Future Oncol; 2018 May; 14(10s):25-49. PubMed ID: 29768052
[TBL] [Abstract][Full Text] [Related]
18. Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review.
Fadare O
Adv Anat Pathol; 2011 Jan; 18(1):60-74. PubMed ID: 21169739
[TBL] [Abstract][Full Text] [Related]
19. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
20. Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor.
Kondo T; Suehara Y; Kikuta K; Kubota D; Tajima T; Mukaihara K; Ichikawa H; Kawai A
Proteomics Clin Appl; 2013 Jan; 7(1-2):70-8. PubMed ID: 23281253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
